Market capitalization | $46.55m |
Enterprise Value | $100.94m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1.62 |
P/S ratio (TTM) P/S ratio | 0.75 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 809.03% |
Revenue (TTM) Revenue | $62.39m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
5 Analysts have issued a Atara Biotherapeutics Inc forecast:
5 Analysts have issued a Atara Biotherapeutics Inc forecast:
Jun '24 |
+/-
%
|
||
Revenue | 62 62 |
809%
809%
|
|
Gross Profit | 50 50 |
494%
494%
|
|
EBITDA | -162 -162 |
45%
45%
|
EBIT (Operating Income) EBIT | -167 -167 |
46%
46%
|
Net Profit | -181 -181 |
41%
41%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Atara Biotherapeutics, Inc. operates as a clinical stage company, which engages in the development of novel therapeutics for patients with cancer, autoimmune, and viral diseases. Its pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.
Head office | United States |
CEO | Pascal Touchon |
Employees | 225 |
Founded | 2012 |
Website | www.atarabio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.